Merrimack stock rockets 200% immediately after beneficial trial data on Onivyde pancreatic cancer cure
Shares of Merrimack Prescription drugs Inc. MACK, +194.00% skyrocketed 199.5% towards a 4 1/2-year high in morning investing Wednesday, following ...
Read moreDetails
